Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of obinutuzumab in proliferative lupus nephritis in China
CTR20220030Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab in lupus nephritis (LN), systemic lupus erythematosus (SLE), sponsored by Roche. Started Jun 2022; status: active.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20220030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220030.